Elisa Agostinetto: FDA has approved adjuvant ribociclib based on the results of the NATALEE trial presented at ESMO24

Elisa Agostinetto shared a post by MediMix on LinkedIn, adding:

“FDA has just approved adjuvant ribociclib based on the results of the NATALEE trial presented at ESMO24.

In Barcelona I discussed the results of NATALEE and other trials presented at ESMO with MediMix.”

Quoting MediMix’s post:

“Highlights from ESMO 2024! Dr Elisa Agostinetto, medical oncologist at Institut Jules Bordet, shares key findings from early-stage breast cancer trials:

– OptiTrain: Exercise improves survival and reduces risk of recurrence in patients undergoing chemotherapy.
– Neo-CheckRay: Promising results for combining radiation and immunotherapy in luminal B high-risk breast cancer.
– NATALEE: Ribociclib plus endocrine therapy shows significant iDFS benefits at four years.

Discover these updates.

For all ESMO 2024 videos, find the link in the comments!”

Proceed to the video attached to the post.
Source: Elisa Agostinetto/LinkedIn and MediMex/LinkedIn

More Posts featuring Elisa Agostinetto on oncodaily.com

Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.